BPMC vs. MDGL, OGN, IONS, BBIO, APLS, ALPN, NUVL, PRGO, ALKS, and INSM
Should you be buying Blueprint Medicines stock or one of its competitors? The main competitors of Blueprint Medicines include Madrigal Pharmaceuticals (MDGL), Organon & Co. (OGN), Ionis Pharmaceuticals (IONS), BridgeBio Pharma (BBIO), Apellis Pharmaceuticals (APLS), Alpine Immune Sciences (ALPN), Nuvalent (NUVL), Perrigo (PRGO), Alkermes (ALKS), and Insmed (INSM). These companies are all part of the "pharmaceutical preparations" industry.
Madrigal Pharmaceuticals (NASDAQ:MDGL) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their earnings, valuation, dividends, profitability, risk, community ranking, analyst recommendations, institutional ownership and media sentiment.
In the previous week, Blueprint Medicines had 2 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 13 mentions for Blueprint Medicines and 11 mentions for Madrigal Pharmaceuticals. Blueprint Medicines' average media sentiment score of 0.52 beat Madrigal Pharmaceuticals' score of -0.05 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the media.
Madrigal Pharmaceuticals has higher earnings, but lower revenue than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Madrigal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Blueprint Medicines received 67 more outperform votes than Madrigal Pharmaceuticals when rated by MarketBeat users. However, 68.56% of users gave Madrigal Pharmaceuticals an outperform vote while only 68.17% of users gave Blueprint Medicines an outperform vote.
98.5% of Madrigal Pharmaceuticals shares are held by institutional investors. 23.9% of Madrigal Pharmaceuticals shares are held by company insiders. Comparatively, 3.9% of Blueprint Medicines shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Madrigal Pharmaceuticals has a net margin of 0.00% compared to Madrigal Pharmaceuticals' net margin of -203.30%. Madrigal Pharmaceuticals' return on equity of -191.56% beat Blueprint Medicines' return on equity.
Madrigal Pharmaceuticals has a beta of -0.47, meaning that its stock price is 147% less volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.63, meaning that its stock price is 37% less volatile than the S&P 500.
Madrigal Pharmaceuticals currently has a consensus price target of $356.73, suggesting a potential upside of 86.23%. Blueprint Medicines has a consensus price target of $91.57, suggesting a potential downside of 1.91%. Given Blueprint Medicines' stronger consensus rating and higher possible upside, equities analysts plainly believe Madrigal Pharmaceuticals is more favorable than Blueprint Medicines.
Summary
Madrigal Pharmaceuticals beats Blueprint Medicines on 10 of the 18 factors compared between the two stocks.
Get Blueprint Medicines News Delivered to You Automatically
Sign up to receive the latest news and ratings for BPMC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BPMC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Blueprint Medicines Competitors List
Related Companies and Tools
